Does Antiretroviral Therapy Prevent Human T-Lymphotropic Virus 1 Transmission From a Seropositive Donor to a Kidney Transplant Recipient? A Case Report and Literature Review

Exp Clin Transplant. 2024 Aug;22(8):641-646. doi: 10.6002/ect.2024.0178.

Abstract

Human T-lymphotropic virus 1 produces a latent infection and disease with poor prognosis. Although its transmission during solid-organ transplant and development of the disease has been described, it is not clear whether antiretroviral treatment could prevent it. We report the first kidney transplant of a donor with human T-lymphotropic virus positivity to a negative recipient who was under antiretroviral treatment without evidence of transmission. We reviewed the literature, which included reports of 55 solid-organ transplant donors with human T-lymphotropic virus positivity to negative recipients, showing high rates of transmission and disease. The benefits of antiretroviral treatment require evaluation in further studies.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adult
  • Anti-Retroviral Agents / therapeutic use
  • Female
  • HTLV-I Infections* / diagnosis
  • HTLV-I Infections* / transmission
  • Human T-lymphotropic virus 1 / immunology
  • Humans
  • Kidney Transplantation* / adverse effects
  • Latent Infection / diagnosis
  • Latent Infection / immunology
  • Latent Infection / transmission
  • Latent Infection / virology
  • Male
  • Middle Aged
  • Risk Factors
  • Tissue Donors
  • Treatment Outcome

Substances

  • Anti-Retroviral Agents